CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present preclinical data from studies on its autoimmune disease program at the 4th Annual Meeting of the Oligonucleotide Therapeutics Society being held at the Harvard Medical School Conference Center in Boston, October 15-18, 2008. The Company’s presentations describe studies of novel compounds targeted to Toll-like Receptors (TLRs), including the evaluation of TLR antagonist compounds in preclinical models of autoimmune diseases.
